Immunohistochemical expression and clinical significance of suggested stem cell markers in hepatocellular carcinoma

Journal of Pathology and Translational Medicine

Volumn 50, Issue 1, 2016, Pages 52-57

  Sung, Jong Jin ^a   Noh, Sang Jae ^a   Bae, Jun Sang ^a   Park, Ho Sung ^a   Jang, Kyu Yun ^a   Chung, Myoung Ja ^a   Moon, Woo Sung ^a  

^a Chonbuk National University Medical School   (South Korea)

Author keywords

Cancer stem cells; Carcinoma; EpCAM protein; Hepatocellular

Indexed keywords

ALPHA FETOPROTEIN; CD133 ANTIGEN; CD56 ANTIGEN; CYTOKERATIN 19; EPITHELIAL CELL ADHESION MOLECULE; HEPATITIS B SURFACE ANTIGEN; HEPATITIS C ANTIBODY;

ADULT; ALCOHOLISM; ARTICLE; CANCER RECURRENCE; CANCER STEM CELL; CANCER SURVIVAL; CHRONIC HEPATITIS; DISTANT METASTASIS; FEMALE; GENE EXPRESSION; HEPATIC PROGENITOR CELL; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MICROVASCULATURE; MICROVESSEL INVASION; MIDDLE AGED; OVERALL SURVIVAL; PATHOLOGY; RECURRENCE FREE SURVIVAL; TUMOR INVASION;

EID: 84954566747     PISSN: 23837837     EISSN: 23837845     Source Type: Journal    
DOI: 10.4132/jptm.2015.10.09     Document Type: Article

References (28)

1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin 2015; 65: 87-108.
2. El-Serag HB, Marrero JA, Rudolph L, Reddy KR. Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology 2008; 134: 1752-63.
3. Visvader JE. Cells of origin in cancer. Nature 2011; 469: 314-22.
4. Clarke MF, Dick JE, Dirks PB, et al. Cancer stem cells: perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res 2006; 66: 9339-44.
5. Bomken S, Fiser K, Heidenreich O, Vormoor J. Understanding the cancer stem cell. Br J Cancer 2010; 103: 439-45.
6. Bjerkvig R, Tysnes BB, Aboody KS, Najbauer J, Terzis AJ. Opinion: the origin of the cancer stem cell: current controversies and new insights. Nat Rev Cancer 2005; 5: 899-904.
7. Marquardt JU, Factor VM, Thorgeirsson SS. Epigenetic regulation of cancer stem cells in liver cancer: current concepts and clinical implications. J Hepatol 2010; 53: 568-77.
8. Yamashita T, Ji J, Budhu A, et al. EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. Gastroenterology 2009; 136: 1012-24.
9. Durnez A, Verslype C, Nevens F, et al. The clinicopathological and prognostic relevance of cytokeratin 7 and 19 expression in hepatocellular carcinoma: a possible progenitor cell origin. Histopathology 2006; 49: 138-51.
10. Zhu Z, Hao X, Yan M, et al. Cancer stem/progenitor cells are highly enriched in CD133+CD44+ population in hepatocellular carcinoma. Int J Cancer 2010; 126: 2067-78.
11. Chan AW, Tong JH, Chan SL, Lai PB, To KF. Expression of stemness markers (CD133 and EpCAM) in prognostication of hepatocellular carcinoma. Histopathology 2014; 64: 935-50.
12. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. AJCC cancer staging manual. 7th ed. New York: Springer, 2010.
13. Visvader JE, Lindeman GJ. Cancer stem cells: current status and evolving complexities. Cell Stem Cell 2012; 10: 717-28.
14. Yang XR, Xu Y, Yu B, et al. High expression levels of putative hepatic stem/progenitor cell biomarkers related to tumour angiogenesis and poor prognosis of hepatocellular carcinoma. Gut 2010; 59: 953-62.
15. Kim H, Choi GH, Na DC, et al. Human hepatocellular carcinomas with "Stemness"-related marker expression: keratin 19 expression and a poor prognosis. Hepatology 2011; 54: 1707-17.
16. Guo Z, Li LQ, Jiang JH, Ou C, Zeng LX, Xiang BD. Cancer stem cell markers correlate with early recurrence and survival in hepatocellular carcinoma. World J Gastroenterol 2014; 20: 2098-106.
17. Litvinov SV, Balzar M, Winter MJ, et al. Epithelial cell adhesion molecule (Ep-CAM) modulates cell-cell interactions mediated by classic cadherins. J Cell Biol 1997; 139: 1337-48.
18. Went PT, Lugli A, Meier S, et al. Frequent EpCAM protein expression in human carcinomas. Hum Pathol 2004; 35: 122-8.
19. Breuhahn K, Baeuerle PA, Peters M, et al. Expression of epithelial cellular adhesion molecule (Ep-CAM) in chronic (necro-)inflammatory liver diseases and hepatocellular carcinoma. Hepatol Res 2006; 34: 50-6.
20. Yamashita T, Forgues M, Wang W, et al. EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma. Cancer Res 2008; 68: 1451-61.
21. Govaere O, Komuta M, Berkers J, et al. Keratin 19: a key role player in the invasion of human hepatocellular carcinomas. Gut 2014; 63: 674-85.
22. Shan YF, Huang YL, Xie YK, et al. Angiogenesis and clinicopathologic characteristics in different hepatocellular carcinoma subtypes defined by EpCAM and alpha-fetoprotein expression status. Med Oncol 2011; 28: 1012-6.
23. Kimura O, Kondo Y, Kogure T, et al. Expression of EpCAM increases in the hepatitis B related and the treatment-resistant hepatocellular carcinoma. Biomed Res Int 2014; 2014: 172913.
24. Kim H, Park YN. Hepatocellular carcinomas expressing 'stemness'-related markers: clinicopathological characteristics. Dig Dis 2014; 32: 778-85.
25. Zen C, Zen Y, Mitry RR, et al. Mixed phenotype hepatocellular carcinoma after transarterial chemoembolization and liver transplantation. Liver Transpl 2011; 17: 943-54.
26. Yeh CT, Kuo CJ, Lai MW, et al. CD133-positive hepatocellular carcinoma in an area endemic for hepatitis B virus infection. BMC Cancer 2009; 9: 324.
27. Tsuchiya A, Kamimura H, Takamura M, et al. Clinicopathological analysis of CD133 and NCAM human hepatic stem/progenitor cells in damaged livers and hepatocellular carcinomas. Hepatol Res 2009; 39: 1080-90.
28. Tsuchiya A, Kamimura H, Tamura Y, et al. Hepatocellular carcinoma with progenitor cell features distinguishable by the hepatic stem/progenitor cell marker NCAM. Cancer Lett 2011; 309: 95-103.